Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

SML0325

Sigma-Aldrich

Retigabin

≥98% (HPLC)

Synonym(e):

N-(2-Amino-4-(4-fluorbenzylamino)-phenyl)-carbaminsäure-ethylester, D-23129, Ezogabin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C16H18FN3O2
CAS-Nummer:
150812-12-7
Molekulargewicht:
303.33
Beilstein:
8072099
MDL-Nummer:
MFCD04307735
UNSPSC-Code:
12352200
PubChem Substanz-ID:
329825330
NACRES:
NA.77
Preise und Verfügbarkeit sind derzeit nicht verfügbar.

Assay

≥98% (HPLC)

Form

powder

Arzneimittelkontrolle

USDEA Schedule V

Farbe

white to light brown

Löslichkeit

DMSO: >15 mg/mL

Lagertemp.

room temp

SMILES String

FC1=CC=C(CNC2=CC(N)=C(NC(OCC)=O)C=C2)C=C1

InChI

1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)

InChIKey

PCOBBVZJEWWZFR-UHFFFAOYSA-N

Angaben zum Gen

human ... KCNQ1(3784) , KCNQ2(3785) , KCNQ3(3786) , KCNQ4(9132) , KCNQ5(56479)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Biochem./physiol. Wirkung

Retigabine (Ezogabine) is a Kv7.2-7.5 (KCNQ2-5) neuronal potassium channel opener witrh anticonvulsant activity.
Retigabine is a Kv7.2-7.5 potassium channel activator; anticonvulsant.

Piktogramme

Skull and crossbonesEnvironment
GHS06,GHS09

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 1

Lagerklassenschlüssel

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
0000240539
0000240539
0000180398
086M4611V
042M4736V

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 6

1 of 6

Diazoxid

Sigma-Aldrich

D9035

Diazoxid

Icilin ≥97% (HPLC), solid

Sigma-Aldrich

I9532

Icilin

Carbamazepin powder

Sigma-Aldrich

C4024

Carbamazepin

Lamotrigin ≥98%, powder

Sigma-Aldrich

L3791

Lamotrigin

4-Acetamidophenol meets USP testing specifications, 98.0-102.0%, powder

Sigma-Aldrich

A5000

4-Acetamidophenol

Dimethylsulfoxid Hybri-Max™, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%

Sigma-Aldrich

D2650

Dimethylsulfoxid

Martin J Gunthorpe et al.
Epilepsia, 53(3), 412-424 (2012-01-10)
The pharmacologic profile of retigabine [RTG (international nonproprietary name); ezogabine, EZG (U.S. adopted name)], is different from all currently approved antiepileptic drugs (AEDs). Its primary mechanism of action (MoA) as a positive allosteric modulator of KCNQ2-5 (K(v) 7.2-7.5) ion channels
Roger J Porter et al.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 4(1), 149-154 (2007-01-03)
Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase
Gökce Orhan et al.
Expert opinion on pharmacotherapy, 13(12), 1807-1816 (2012-07-13)
Epilepsy is a serious and common chronic neurological disease with an urgent need for novel treatment options, because 30% of all epilepsy patients do not respond to currently available drugs. Retigabine/Ezogabine (RTG) is a third-generation antiepileptic drug (AED) with a
Michele A Faulkner et al.
Expert opinion on drug safety, 12(6), 847-855 (2013-07-26)
Complex-partial seizures are frequently resistant to antiepileptic therapy. Two new medications with mechanisms of action novel within the antiepileptic class have recently received approval for the adjunctive treatment of partial (focal) seizures. A Medline search was conducted to identify preclinical
Philip N Patsalos et al.
Expert opinion on pharmacotherapy, 13(5), 699-715 (2012-03-13)
The search for new, more effective antiepileptic drugs (AEDs) continues. The three most recently approved drugs, the so-called third-generation AEDs, include lacosamide, retigabine and eslicarbazepine acetate and are licensed as adjunctive treatment of partial epilepsy in adults. For the above
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.